Dabigatran and Ketoconazole: Interaction Details

Brand names
Ketoconazole
NizoralKetodanRecorlev +9 more
Dabigatran
Pradaxa
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Ketoconazole

Brand names
  • Nizoral
  • Ketodan
  • Recorlev
  • Kuric
  • Xolegel
  • Extina
  • Anti Dandruff
  • Anti-dandruff
  • Gembooxt Ketoconazole 1% Medicated Shampoos
  • KetoconClear Cream
  • Sent From Earth Vita Scalp Revive
  • Tagrit Antifungal Treament Ketoconazole

What Happens When You Take Dabigatran With Ketoconazole

What can happen when they are taken together (rated Major)

Increased dabigatran exposure and an increased risk of bleeding

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Because dabigatran is a and ketoconazole is a P-gp , giving the two together may raise dabigatran exposure and the likelihood of bleeding, with renally impaired patients at particular risk. For adults taking dabigatran capsules to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation, the combination should be avoided when CrCl is 15 to 30 mL/min; when CrCl is 30 to 50 mL/min and ketoconazole cannot be avoided, the dabigatran dose should be lowered to 75 mg twice daily.

When dabigatran is used to treat DVT or pulmonary embolism (PE), to reduce the risk of their recurrence, or for prophylaxis of these events after hip surgery, should be avoided if CrCl is below 50 mL/min. In patients with CrCl of 50 mL/min or higher receiving prophylaxis, the two drugs should be given several hours apart.

No studies have examined dabigatran given with P-gp in pediatric patients, although dabigatran exposure may rise in this population.1 In elderly patients, avoiding the use of a P-gp inhibitor together with dabigatran should be considered.2 Regardless of kidney function, caution may be warranted when dabigatran is combined with moderate to strong P-gp inhibitors.3

The Dabigatran and Ketoconazole Interaction, Explained

Dabigatran (Pradaxa) is a that helps prevent dangerous clots. Ketoconazole, especially when taken by mouth, can block a natural "pump" in your body that helps move dabigatran out. When that pump is blocked, more dabigatran can stay in your blood. That can raise your chance of bleeding, such as easy bruising, nosebleeds, bleeding gums, or dark stools. The risk is higher if your kidneys don't work as well or if you are older. This concern is based mostly on how these drugs work, but it is still taken seriously.

The good news is that your care team can manage this. Please don't stop anything on your own. Talk with your pharmacist or doctor.

Mechanism: Ketoconazole inhibits intestinal and efflux, increasing and exposure of dabigatran (a ), which raises bleeding risk. The greatest concern is with renal impairment. Severity: major. Onset is not specified. The evidence rating on file is theoretical.

  • NVAF, CrCl 15 to 30 mL/min: avoid the combination.
  • NVAF, CrCl 30 to 50 mL/min: reduce dabigatran to 75 mg BID if is necessary.
  • DVT/PE treatment, recurrence reduction, or post-hip surgery prophylaxis, CrCl under 50 mL/min: avoid the combination.
  • Prophylaxis, CrCl 50 mL/min or higher: separate the doses by several hours.
  • Consider avoiding the combination in elderly patients. It has not been studied in pediatric patients. Use caution regardless of renal function, and monitor CrCl and for signs of bleeding.

See the 4 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Dabigatran and Ketoconazole Interact

The likely mechanism

of -mediated efflux transport of dabigatran

In short: Ketoconazole slows P-glycoprotein, a pump that moves dabigatran out of cells, so more dabigatran can stay in the body.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When One Drug Raises Another’s Level”, one chapter of our one-minute explainer. See how it works 

How to Manage the Dabigatran and Ketoconazole Interaction

Your care team has several ways to handle this combination safely:

  • They will check your kidney function, because it guides which approach they choose.
  • Depending on why you take dabigatran and how well your kidneys work, they may lower your dabigatran dose, space the two medicines several hours apart, or choose a different medicine.
  • Your team may monitor you more closely, especially if you are an older adult.

What you can do: Keep taking your medicines as prescribed. Tell your pharmacist or prescriber about both medicines. Report any unusual bruising, bleeding, blood in your urine, or black stools right away.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Dabigatran or Ketoconazole need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

3 reports from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses

    A 76-year-old woman receiving dabigatran 150 mg twice daily for bilateral lower extremity DVTs, along with low-dose quiNIDine (10 mg twice daily) for an unknown indication, was admitted from a nursing home with abdominal pain and rectal bleeding. Upon admission, she had anemia (Hb, 4.9 g/dL) and coagulopathy (thrombin time (TT) greater than 60 seconds), together with acute kidney injury (SCr of 2 mg/dL; baseline 0.8 mg/dL) and an elevated BUN of 90 mg/dL.

    The diagnosis was acute blood loss anemia secondary to lower bleeding, likely related to dabigatran use. Hemodialysis was not started because of the bleeding risk associated with catheter placement.

    Transfusion measures and idaruCIZUmab therapy initially normalized her Hb (8.2 g/dL) and TT (14.3 seconds); however, she rebled, and the TT was again greater than 60 seconds when rechecked approximately 20 hours after idaruCIZUmab administration. She required a 10-day hospitalization for persistent coagulopathy, rectal bleeding, and impairment, during which she received 2 additional doses of idaruCIZUmab on hospital days 2 and 4, each producing only temporary normalization of coagulation parameters.

    Rectal bleeding persisted until day 5, when it began to improve, although TT stayed elevated until hospital day 9. Although renal impairment may have contributed to reduced dabigatran in this case, quiNIDine (a ) was thought to have contributed to the initially suspected supratherapeutic dabigatran levels.4

  2. Report 2 · Study title

    Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function

    A comparative effectiveness study in patients with nonvalvular atrial fibrillation and normal kidney function found that the overall bleeding rate was 52% higher (244.9 vs 158.4 per 1000 person-years; HR, 1.52; 95% CI, 1.05 to 2.2) when dabigatran was coadministered with verapamil or dilTIAZem (n=750) than when it was coadministered with amLODIPine (n=1316), and 43% higher (291.3 vs 199.7 per 1000 patient-years; HR, 1.43; 95% CI, 1.02 to 2) with dabigatran and verapamil or dilTIAZem (n=764) than with metoprolol (n=1334). Compared with amLODIPine, dabigatran with verapamil or dilTIAZem was also associated with significant increases in overall () bleeding (HR, 2.16; 95% CI, 1.3 to 3.6), minor bleeding (HR, 1.56; 95% CI, 1.07 to 2.27), and GI minor bleeding (HR, 2.16; 95% CI, 1.29 to 3.63).

    Compared with metoprolol, dabigatran with verapamil or dilTIAZem was associated with significant increases in overall GI bleeding (HR, 2.32; 95% CI, 1.42 to 3.79), major/moderate bleeding (HR, 3.32; 1.54 to 7.16), major/moderate GI bleeding (HR, 5.49; 95% CI, 1.67 to 18.03), and GI minor bleeding (HR, 2.33; 95% CI, 1.42 to 3.82). The dabigatran dose was 150 mg twice daily. Caution may be necessary when dabigatran is coadministered with verapamil and dilTIAZem, and possibly other moderate to strong , irrespective of kidney function.3

  3. Report 3 · Study title

    Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation

    In a study of patients 66 years or older (median, 82 years) with major (n=1117 cases and 4465 controls), of dabigatran with simvastatin (n=502) or lovastatin (n=27), both , significantly raised the risk of major hemorrhage by 46% relative to other not implicated in P-gp (atorvastatin, pravastatin, fluvastatin or rosuvastatin). Compared with other statins, simvastatin alone was associated with a significant 44% increase in major hemorrhage risk, whereas lovastatin alone was associated with a nonsignificant 90% increase.2

Dabigatran and Ketoconazole: Common Questions

How serious is the Dabigatran and Ketoconazole interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Dabigatran and Ketoconazole interaction managed?

Your care team has several ways to handle this combination safely: They will check your kidney function, because it guides which approach they choose. Depending on why you take dabigatran and how well your kidneys work, they may lower your dabigatran dose, space the two medicines several hours apart, or choose a different medicine. Your team may monitor you more closely, especially if you are an o… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Dabigatran and Ketoconazole Interaction

Ask in your own words about taking Dabigatran and Ketoconazole together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (4)

  1. Product Information: PRADAXA(R) oral capsules, dabigatran etexilate oral capsules. Boehringer Ingelheim Pharmaceuticals Inc (per FDA), Ridgefield, CT, 2023. DailyMed
  2. Antoniou T, Macdonald EM, Yao Z, et al: Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. CMAJ 2017; 189(1):E4-E10. PubMed
  3. Pham P, Schmidt S, Lesko L, et al: Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function. JAMA Netw Open 2020; 3(4):e203593-. DOI
  4. George S, Taburyanskaya M, & Lewis V: Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses. Blood Coagul Fibrinolysis 2019; 30(1):42-46. PubMed
Was this write-up helpful?

Other Serious Interactions of Dabigatran and Ketoconazole

Also serious with Ketoconazole

Also serious with Dabigatran

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Ketoconazole

With Dabigatran

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.